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Introduction
Recessive dystrophic epidermolysis bullosa, generalized 
severe (RDEB-gen sev; OMIM# 226600) is a devastating 
skin blistering disease. The disease is caused by bi-allelic 
null mutations in the COL7A1 gene encoding type VII colla-
gen.1 Type VII collagen is the major component of anchoring 
fibrils that secure attachment of the epidermis to the dermis 
and is expressed by both basal epidermal keratinocytes 
and dermal fibroblasts.2 The absence of type VII collagen 
in RDEB-gen sev leads to severe blistering of the skin and 
mucosa just below the lamina densa. Abnormal wound heal-
ing with excessive scarring inevitably results in the fusion of 
fingers and toes (i.e., pseudosyndactyly).3 Patients have a 
highly increased risk of developing aggressive squamous 
cell carcinomas, which is the major cause of death before 
the age of 30–40 years.4 The COL7A1 gene comprises 118 
small exons that encode the type VII collagen pro-α1 chain, 
which consists of a central 145 kDa triple helix domain (THD) 
flanked by a 145 kDa amino-terminal non-collagenous 1 
(NC1) domain and a 30 kDa carboxyl-terminal non-collage-
nous 2 (NC2) domain.5 Post-translational modification leads 
to stable trimerization of three pro-α1 chains to pro-type VII 
collagen homotrimers, followed by partial removal of the NC2 
domain and antiparallel dimerization of type VII collagen 
trimers.6 Numerous type VII collagen dimers aggregate lat-
erally to form anchoring fibrils that attach the epidermis to 
the dermis. Notably, all exons that encode the triple helix are 
in-frame and most encode repetitive glycine-X-Y amino acid 
sequences, where X and Y can be any amino acid.
At the moment, treatment for RDEB-gen sev is merely 
symptomatic. Several therapeutic approaches have been 
studied,7–12 however, there still is a great need for novel and, 
highly preferably, systemic approaches. Antisense oligo-
nucleotide (AON)-mediated exon skipping seems to be an 
attractive therapeutic approach for RDEB-gen sev. In this 
approach, short modified RNA molecules (e.g., 2’-O-methyl 
phosphorothioates, locked nucleic acids, or phosphorodi-
amidate morpholinos) are designed to modulate pre-mRNA 
splicing of specific in-frame target exons harboring the dis-
ease-causing mutation. Through complementary binding 
of the AON to the target exon, the exon is hidden from the 
splicing machinery and spliced out with its flanking introns, 
bypassing the mutation and allowing the production of an 
internally deleted, but in the ideal outcome, functional pro-
tein.13 COL7A1 is a good candidate gene for AON-mediated 
exon skipping, as most RDEB-gen sev patients have small 
exonic mutations, and most COL7A1 exons are in-frame and 
encode highly repetitive Gly-X-Y amino acid stretches. This 
is underscored by findings that patients carrying COL7A1 
mutations that lead to natural skipping of an in-frame exon 
have relatively mild phenotypes.14,15 Additionally, the sever-
ity of the clinical phenotype in RDEB is highly correlated to 
the level of expression of type VII collagen at the cutaneous 











Official journal of the American Society of Gene & Cell Therapy
Exon Skipping as Systemic Therapy for RDEB
Bremer et al.
The “generalized severe” form of recessive dystrophic epidermolysis bullosa (RDEB-gen sev) is caused by bi-allelic null 
mutations in COL7A1, encoding type VII collagen. The absence of type VII collagen leads to blistering of the skin and mucous 
membranes upon the slightest trauma. Because most patients carry exonic point mutations or small insertions/deletions, most 
exons of COL7A1 are in-frame, and low levels of type VII collagen already drastically improve the disease phenotype, this 
gene seems a perfect candidate for antisense oligonucleotide (AON)-mediated exon skipping. In this study, we examined the 
feasibility of AON-mediated exon skipping in vitro in primary cultured keratinocytes and fibroblasts, and systemically in vivo 
using a human skin-graft mouse model. We show that treatment with AONs designed against exon 105 leads to in-frame 
exon 105 skipping at the RNA level and restores type VII collagen protein production in vitro. Moreover, we demonstrate that 
systemic delivery in vivo induces de novo expression of type VII collagen in skin grafts generated from patient cells. Our data 
demonstrate strong proof-of-concept for AON-mediated exon skipping as a systemic therapeutic strategy for RDEB.
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basement membrane zone (BMZ); the slightest increase in 
type VII collagen deposition at the BMZ already leads to a 
marked improvement in clinical phenotype.16
Pioneer attempts to induce exon skipping in COL7A1 have 
been described before: Turczynski et al. induced exon skip-
ping in vitro, while Goto et al. were able to induce localized 
exon 70 skipping in vivo.17,18 However, the severe multi-organ 
involvement in RDEB demands a generalized treatment 
approach, which renders systemic delivery of AONs crucial 
to therapeutic success. In this study, we have therefore taken 
the exon skipping approach a leap forward to clinical applica-
tion by demonstrating the potential of systemic delivery of the 
AONs using an in vivo grafting model.
Results
Selection of exons eligible for exon skipping
To study the applicability of exon skipping in the COL7A1 
gene, all 118 exons of COL7A1 were analyzed in silico 
(summarized in Figure 1, NCBI reference sequence: 
NM_000094.3). Out of 118 exons, 107 are in-frame, i.e., more 
than 90%. The THD of type VII collagen protein is encoded 
solely by in-frame exons and consists of 84 exons that col-
lectively encode 454 Gly-X-Y amino acid sequence repeats. 
Interestingly for exon skipping, 60 of these 84 exons encode 
perfect Gly-X-Y sequence motifs only, ranging from 3–13 
Gly-X-Y triplets (collectively 337/454 triplets). Moreover, the 
reading frame of all exons in the THD start at position 1 and 
end at position 3. Hence, skipping of one of these exons will 
not result in an amino acid change at the skipping junction 
and leave the Gly-X-Y repeat structure intact. The Gly-X-
Y sequence is essential for triple helix formation, however, 
the length of the triple helix is not essential for its function.19 
Therefore, it is predicted that skipping of an exon encoding a 
Gly-X-Y sequence only will have the least functional conse-
quences. The in-frame nature of the 107 exons, the Gly-X-Y 
repeat structure, and the reading frame, makes Figure 1 a 
roadmap for exon skipping therapy in the COL7A1 gene.
For this study, exon 105 was chosen as a target, as primary 
keratinocyte and fibroblast cultures were readily available 
from patient EB-023 suffering from RDEB-gen sev due to the 
homozygous nonsense mutation c.7828C>T, p.Arg2610Ter 
in exon 105. This nonsense mutation introduces a premature 
termination codon (PTC), which induces nonsense-mediated 
mRNA decay (NMD), resulting in the total absence of type VII 
collagen in the patient’s skin explaining the severe phenotype 
(Supplementary Figure S1). Additionally, exon 105 is an 
81 bp in-frame exon that encodes nine Gly-X-Y repeats, and, 
as such, skipping of exon 105 is predicted to be tolerated.
In vitro exon skipping results in restoration of type VII 
collagen synthesis
According to published data on AON design,12 all 1,134 
possible 17–23 base pair long sequences in the region of 
exon 105, were analyzed in silico for their Tm (>48 °C), GC-
content (40–60%), binding energy (15–30), and off target 
binding. Splice enhancer sequences in and around exon 
105 were visualized using prediction software.20 The two 
most promising sequences were synthesized as 2’-O-methyl 
phosphorothioate AONs and analyzed for their exon skipping 
abilities (Figure 2a). PCRs using primers spanning exon 
102–108 were used to assess exon skipping and possible 
nearby upstream or downstream splice effects. Optimization 
of the in vitro transfection experiments in control cells showed 
that the highest exon-skipping efficiency was achieved using 
a combination of both AONs in a total concentration of 250 
nmol/l (Figure 2b). This combination was used in further 
experiments.
Control and patient primary keratinocytes and fibroblasts 
were subsequently cultured and transfected with the com-
bination of the two specific exon 105 AONs or non-specific 
AONs. Forty-eight hours after transfection, RNA was isolated 
from transfected control and patient keratinocytes and fibro-
blasts. In the control and patient cells transfected with the 
exon 105 AONs, RT-PCR analysis revealed exon skipping 
with a high efficiency at the RNA level in both control and 
patient keratinocytes and fibroblasts. Exon 105 deletion was 
confirmed by Sanger sequencing (Figure 2c).
To assess de novo expression of type VII collagen result-
ing from exon 105 skipping, control and patient cells were 
cultured on cover slips prior to transfection with the two 
exon 105 AONs. Seventy-two hours after transfection, 
the cells were fixated to the cover slips and analyzed by 
Figure 1 Road map for exon skipping in the COL7A1 gene. The figure represents all COL7A1 exons and their corresponding reading 
phases. The shapes of the exons depict the phasing of the triplet codons over different exons. Light and dark green boxes indicate skippable 
exons, which can be divided into two groups: those that start and end with a complete codon (square boxes), all but one located in the triple-
helix domain (THD) domain, and those that begin and end with a partial codon (arrow shaped boxes), located exclusively in the NC1 and NC2 
domains. Red boxes depict unskippable exons. Exons 29 to 112 encode the collagenous THD. Dark green boxes depict exons of the THD that 
encode a Gly-X-Y amino acid sequence only.
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Figure 2 Specific antisense oligonucleotides (AONs) restore type VII collagen synthesis in vitro. (a) Position of AON1 and AON2 and 
patient’s mutation (red arrow) in exon 105. Predicted exon splice enhancer sequences reveal two potential regions for AON targeting (pink 
bars and orange curve). (b) RT-PCR on patient keratinocytes showed most effective exon skipping with 250 mmol/l of both AONs. Healthy 
keratinocytes (1), Scrambled AONs (2–3), 250 mmol/l and 500 mmol/l AON1 (4–5), AON2 (6–7) or AON1+AON2 (8–9). (c) RT-PCR on healthy 
and patient keratinocytes and fibroblasts after transfection with 250 mmol/l AONs (3–4 and 7–8 respectively) or scrambled AON (1–2 and 
5–6 respectively). Lower panel shows confirmation of exon 105 skipping by Sanger sequencing. (d) Cells immunostained for type VII collagen 
treated or untreated with 250 mmol/l AONs (percentage represents the number of type VII collagen  expressing cells). Scale bar = 15 µm. (e) 
Western blot analysis on healthy control, untreated patient, and treated patient keratinocyte cell lysates, reveals the expression of type VII 
collagen by transfected patient keratinocytes. (f) Dot blot analysis on conditioned medium reveals that the newly formed Δ105 type VII collagen 
can be secreted. N.B. Due to overexpression of the membrane, and the use of a polyclonal antibody, the blots in e and f showed minor residual 
staining in untreated patient cells, whereas no staining was observed with LH7.2 monoclonal antibody in d.
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immunofluorescence (IF) staining. In contrast to control kera-
tinocytes and fibroblast, no expression of type VII collagen 
was observed in patient cells, either untransfected or trans-
fected with a nonspecific AON. However, when patient kera-
tinocytes and fibroblasts were transfected with the specific 
AONs against exon 105, a distinct de novo expression of type 
VII collagen was observed (Figure 2d). Compared to healthy 
control cells, restoration of type VII collagen expression was 
observed in 50 and 33% of transfected patient keratinocytes 
and fibroblasts, respectively. Restoration of protein synthesis 
was calculated by examining 1,500 cells for type VII collagen 
expression for each transfection condition.
Western blot analysis on protein lysates from patient cells 
treated with AONs for 72 hours showed that treated patient 
cells synthesized the full length of the exon 105 deleted type 
VII collagen. Moreover, the level of type VII collagen restora-
tion was 14% compared to healthy control cells (Figure 2e). 
Further, dot blot analysis on conditioned medium revealed 
that the newly synthesized type VII collagen lacking the 
amino acids encoded by exon 105 could be secreted by the 
transfected patient cells (Figure 2f).
Systemically induced restoration of type VII collagen 
expression in vivo
To establish preclinical relevance, the AONs were tested in 
an in vivo model.21 To this end, we reconstituted skin grafts 
of primary cultured patient fibroblasts and keratinocytes on 
the back of athymic immune-deficient nude mice  (Figure 3a, 
Supplementary Figure S2). IF staining specifically for human 
type VII collagen showed brightly positive staining of the BMZ 
in the human skin graft and negative staining in mouse skin. 
Thus, this skin graft model represents a personalized mouse 
model offering the opportunity to easily and directly test the in 
vivo efficacy of AONs on patient skin and additionally allows 
long-term treatment and observation of treatment effect on 
the target skin.
Six mice were grafted with patient keratinocytes and fibro-
blasts carrying the premature termination codon c.7828C>T;p.
Arg2610Ter mutation in exon 105, and two mice were grafted 
with healthy control keratinocytes and fibroblasts. During the 
treatment phase, four out of the six mice bearing patient skin 
grafts were treated with five times a week 50 mg/kg of each 
AON (100 mg/kg in total) via subcutaneous injections at the 
tail base, i.e., approximately 7 cm distal from the skin grafts, 
for a period of 8 weeks (injection site indicated in Figure 3a). 
The two remaining mice bearing patient skin grafts, and the 
two mice bearing healthy control skin grafts were given sub-
cutaneously injected saline solution as a negative control.
The total AON dose of 100 mg/kg was used because pre-
vious pharmacodynamics and pharmacokinetics studies for 
Duchenne muscular dystrophy (DMD) showed saturation 
of serum protein binding beyond this concentration.22 The 
choice for the subcutaneous administration route was based 
on our positive experience with a DMD mouse model (mdx) 
where dystrophin exon skipping could be detected in skin 
samples (data not shown), and the absence of differences 
in bioavailability of 2’-O-methyl phosphorothioates injected 
either subcutaneously or intravenously.22
After 8 weeks of treatment, the human skin grafts were 
harvested and RNA was isolated from graft cryosections. 
Subsequent RT-PCR analysis revealed exon 105 skipping 
in the RNA isolated from the patient grafts grown on mice 
treated with the specific exon 105 AONs. Sanger sequencing 
confirmed exon 105 skipping (Figure 3b). As expected, exon 
105 skipping was not observed in RNA isolated from the 
patient or control grafts grown on mice injected with saline 
solution.
Further, human skin graft cryosections were immunos-
tained for human type VII collagen, which revealed bright 
staining at the BMZ in control graft sections treated with 
saline and complete absence of type VII collagen expression 
in patient graft sections treated with saline. In contrast, clear 
de novo expression of type VII collagen at the BMZ was evi-
dent in patient graft sections isolated from mice treated sys-
temically with the specific exon 105 AONs (Figure 3c). The 
staining intensity of type VII collagen varied along the BMZ 
and the overall amount of type VII collagen expression was 
lower than in the control graft sections, however, restoration 
of type VII collagen expression was unequivocally observed. 
Immunostaining for type IV collagen in untreated patient skin 
grafts revealed typical RDEB basement membrane abnor-
malities with clear widening of the BMZ and off-shoots deep 
into the papillary dermis (Figure 3d). Interestingly, such 
basement membrane deformities were neither observed 
in the treated patient skin grafts, nor in the healthy control 
grafts. These results do not only show efficacy of the AON 
treatment, but also advocate the functionality of the de novo 
Δ105 type VII collagen protein expressed in treated patient 
skin grafts.
Discussion
Several therapeutic strategies for RDEB are being investi-
gated at cell, protein, RNA, or DNA level.23,24 For example, the 
injection of type VII collagen expressing fibroblasts,25 induced 
pluripotent stem cells as a source for the regeneration of 
healthy skin,8,26 placenta-derived stem cell strategies,27 and 
ex vivo gene editing.12 Another group of promising therapeu-
tic approaches is acting either through or on RNA transcripts, 
e.g. translational premature termination codon read-through, 
trans-splicing, and in vitro transcribed RNAs (extensively 
reviewed in ref. 23) Although several of these strategies have 
shown encouraging results in preclinical research and early 
clinical trials, further studies and trials are needed to fully 
understand the safety and efficacy of these approaches and 
determine their clinical applicability. Hence, there still is an 
unmet need for the patients, warranting research into novel, 
especially systemic, therapeutic strategies.
We here studied AON-mediated exon skipping as sys-
temic therapeutic approach for RDEB. The potential of AON-
mediated exon skipping is underscored by clinical studies in 
several genetic diseases,28 but it is most advanced in Duch-
enne muscular dystrophy. A previous study by Turczynski et 
al., investigating exon skipping in COL7A1, showed exon 
skipping in vitro,17 whereas Goto et al. showed exon 70 
skipping and restoration of type VII collagen expression 16 
hours after a single local injection directly into a transplanted 
skin equivalent on the back of rats.19 However, the observed 
exon skipping efficiency was rather low in the latter study as 
www.moleculartherapy.org/mtna
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Figure 3 In vivo antisense oligonucleotide (AON)-induced exon skipping leads to restoration of type VII collagen synthesis upon 
systemic treatment. (a) Illustration of the skin-humanized mouse model. Primary control keratinocytes and fibroblasts were seeded into 
silicone grafting chambers implanted on the back of athymic nude mice. The injection site is indicated (grey dotted circle). (b) RT-PCR showed 
in vivo exon 105 skipping after eight weeks of treatment. Saline treated healthy and patient skin grafts (lane 1 and 2, respectively) show only 
a wild-type RNA product including exon 105, whereas patient skin grafts from specific AON-treated mice revealed skipping of exon 105 (lane 
3). Sanger sequencing confirmed skipping of exon 105. (c) IF staining on cryosections of grafts from mice treated as in a, revealed de novo 
expression of type VII collagen (green) in patient grafts grown on AON-treated mice. Type VII collagen expression varied along the BMZ and 
the overall amount of protein expression was reduced compared to the control graft. (d) Staining for type IV collagen (red), reveals widening 
and off shoots of the basement membrane zone in untreated patient skin grafts, indicated by white arrows. This widening is neither observed 
in healthy control nor treated patient skin grafts. Dotted line indicates graft border, and human (H) and mouse (M) epidermis is indicated. 
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shown by RNA and type VII collagen expression analyses. 
Further, during the revision of this manuscript another study 
on exon skipping for COL7A1 was published.29 Turczynski et 
al., showed in vivo restoration of type VII collagen expression 
and anchoring fibrils in a human skin graft mouse model after 
one or two local injections with AONs targeting exons 73 and 
74, or 80. In vitro, 20% of patient keratinocytes regained type 
VII collagen expression. By thorough in silico selection of 
AONs, we were able to achieve high exon skipping efficiency 
at the RNA level, and restoration of protein expression in vitro 
in 50% of patient keratinocytes, at a total level of approxi-
mately 14% compared to control cells. The intensity of type 
VII collagen staining of treated patient cells positive for type 
VII collagen was comparable to healthy control cells.
Subsequently, we elaborated on the clinical relevance of 
AON-mediated exon skipping for RDEB by investigating the 
effect of systemic AON administration on patient skin grown 
on the back of nude mice. Systemic treatment is highly pre-
ferred for the RDEB-gen sev patient population, as RDEB 
also affects the internal lining of several organs, such as the 
esophagus and genital mucosa.1 Our in vivo data demon-
strate, for the first time, that AONs administered systemically 
by subcutaneous injections induce exon skipping and res-
toration of type VII collagen protein synthesis at a distance 
from the injection site, providing proof-of-concept for AON-
mediated exon skipping as a systemic treatment for RDEB.
Separately, we have studied the effect of exon skipping 
on the functionality of type VII collagen.19 Type VII collagen 
lacking the amino acids encoded by exon 105 showed con-
served functionality in various biochemical and in vitro cell 
assays. Triple helix thermostability, fibroblast migration and 
adherence were all comparable to wild-type type VII collagen 
protein. Moreover, upon injection of type VII collagen lacking 
exon 105 in a type VII collagen hypomorphic mouse model, 
normal incorporation in the basement membrane zone was 
observed. Our observations that the newly formed type VII 
collagen lacking exon 105 is normally incorporated in the 
graft’s BMZ, whereas it is known that several dominantly 
inherited mutations cause aberrant type VII collagen deposi-
tion patterns at the BMZ,30 further supports the lack of strong 
functional consequences of exon 105 skipping.
It is yet unknown which cell type is responsible for the res-
toration of type VII collagen expression upon AON treatment: 
keratinocytes, fibroblasts, or both. Notably, a higher number 
of basal keratinocytes show expression of type VII colla-
gen, compared to dermal fibroblasts, as can be also seen 
in Figure 2d. Therefore, the treatment effect is anticipated 
to be higher if the systemically administered AONs reach 
the basal keratinocytes. Targeting only the dermal fibroblasts 
may, however, already result in significant amelioration of the 
phenotype, as indicated by the clinical improvement seen 
after injections with type VII collagen expressing fibroblasts.25 
Moreover, as shown by fibroblast injections in type VII colla-
gen hypomorphic mice followed by type VII collagen expres-
sion and skin integrity analyses, 30–35% of type VII collagen 
expression levels are sufficient to prevent skin fragility.31 In 
combination with the strong type VII collagen expression—
phenotype correlation,16 complete restoration of type VII col-
lagen expression seems not a prerequisite for successful 
exon skipping with significant phenotypic improvement.
AON-mediated exon skipping is preeminently a precision 
medicine approach, which is especially true for the COL7A1 
gene, where most mutations are scattered throughout the 
entire 118 exons. However, looking at the COL7A1 muta-
tion database of more than 670 published mutations in over 
1,000 DEB patients (www.deb-central.org), 70–75% of all 
RDEB mutations are located in in-frame exons and almost 
40% are located in exons encoding Gly-X-Y motifs only.32–34 
Treating all these patients would thus require an AON-library 
targeting most (if not all) of the 107 in-frame COL7A1 exons. 
As each AON is considered a new drug, this will pose chal-
lenges in, for instance, trial design due to the limited num-
ber of patients. However, in case one or two medicinal AONs 
for RDEB would have obtained marketing authorization, this 
would allow discussions with the regulators on extrapolation 
of data on efficacy and safety for AONs with identical chem-
istries,35 thereby facilitating the development of AONs for a 
larger group of patients with RDEB.
Translation into the clinic will undoubtedly come with 
challenges. A lot can, however, be learned from studies 
performed in Duchenne muscular dystrophy where AON-
mediated exon skipping with 2’-O-methyl phosphorothioate 
AONs has now been tested in more than 300 patients.36–38 No 
serious adverse effects have been noted that would preclude 
its clinical application and the AON treatment is generally 
well tolerated. However, transient proteinuria and thrombocy-
topenia occur more frequently in AON than placebo-treated 
cohorts.38 Subcutaneously injected oligonucleotides cause 
injection site reactions like redness, irritation and induration. 
In RDEB, where the skin of the patient is severely affected 
and fragile and injection site reactions might worsen the dis-
ease, intravenous administration might therefore be the pre-
ferred delivery route of the AONs.
In conclusion, this study provides strong proof of con-
cept for systemic treatment of generalized severe recessive 
dystrophic epidermolysis bullosa by AON-mediated exon 
skipping.
Materials and methods
Ethics statement. Informed consent was obtained before the 
use of healthy control and patient skin according to the Dec-
laration of Helsinki Protocols. The institutional animal care 
and use committee approved the use of all experimental ani-
mals for this study. The mice were housed in a clean facility 
and provided with water and nutrition ad libitum.
Cell culture. Control keratinocytes and fibroblasts were iso-
lated from skin after informed consent of healthy patients 
that underwent reconstructive surgery. RDEB patient 
keratinocytes and fibroblasts were isolated from a biopsy 
after informed consent of a patient having the homozy-
gous c.7828C>T, p.Arg2610Ter null mutation in exon 105 
of the COL7A1 gene. After incubation of the skin in tryp-
sin  (Invitrogen, Carlsbad, CA) for 1 hour at 37 °C 5% CO2, 
the epidermis sheet was separated from the dermis with 
tweezers. Subsequently, the epidermis was cut into small 
~1 × 1 mm pieces followed by a 5 to 10 minutes incubation in 
trypsin (Invitrogen) at 37 °C for separation. Bovine calf serum 
www.moleculartherapy.org/mtna
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(BCS) (Gibco, Life Technologies, Bleiswijk, the Netherlands) 
was added to the solution to stop trypsinization. The cells 
were pelleted by centrifugation for 10 minutes at 200 g and 
resuspended in complete Cnt-07 (CELLnTEC Advanced Cell 
Systems AG, Bern, Switzerland) serum-free medium to be 
plated into a culture petri dish. For continuation of culture, 
the cells are split in 3 when 90% confluence was reached. 
The dermis tissue obtained after the first trypsinization step 
described above, was cut into small pieces and spread to 
the bottom of a culture petri dish. Culture medium was daily 
added drop-wise to prevent floating of the tissue. Once the 
tissue-surrounding area was confluent with fibroblasts, the 
tissue was removed from the petri dish and the monolayer 
cells were harvested and seeded into a new petri dish. For 
continuation of culture, the cells were split in 3 when 90% 
confluence was reached. For the culture of fibroblasts, a mix-
ture with a 6:4 ratio of F-12 nutrient (Gibco) (completed with 
10% BCS (Gibco), glutamin (Invitrogen), streptomycin (Invit-
rogen), and penicillin (Invitrogen)) and Amniochrome (Lonza, 
Cologne, Germany) was used.
Antisense oligonucleotides. Two specific AONs were used to 
induce skipping of exon 105 of the COL7A1 gene. AON1, 
5’-GAUACCAGGCACUCCAUCCU-3’, and AON2, 5’-CAUGAA 
GCCAACAUCUCCUU-3’. A nonspecific AON 5’-GCUUUU 
CUUUUAGUUGCUGC-3’ was used as negative control and 
with the addition of a 5’-FAM 537.46 fluorescent label as pos-
itive control. All AONs comprise 2’ O-methyl modified bases 
and phosphorothioate linkages, and were synthesized and 
purified by reverse-phase high-performance liquid chroma-
tography (Eurogentec BV, Liège, Belgium).
In vitro transfection.  In vitro cationic lipid transfection experi-
ments were performed in 12-well plates using polyethyleni-
mine (PEI) (MBI Fermentas, Life Technologies, Bleiswijk, 
the Netherlands) and Lipofectamine-2000 (LF) (Invitro-
gen). The lipid-AON complex formation was optimized to a 
weight:weight ratio of 1:1 for both PEI and LF. PEI was used 
to transfect fibroblasts and LF was used to transfect kerati-
nocytes. Prior to transfection, cells were grown to 70–80% 
confluency, washed, and fresh medium was added to the 
wells. For the transfection using LF, the medium was replaced 
with Opti-MEM (Gibco). Lipid-AON complexes were formed 
according to the manufacturer’s protocol and drop-wise 
added to the cells at a final concentration of 250 nmol/l of 
AON in the medium. After six hours of incubation at 37 °C 
5% CO2 the medium was removed, cells were washed, and 
complete culture medium was added.
In vitro RNA and protein analysis. For the analysis of exon 
skipping on RNA level, RNA was isolated 48 hours after 
transfection using RNeasy Micro Kit (Qiagen, Hilden, Ger-
many). Medium was removed from the wells prior to the add-
ing of the lysis buffer (provided by the kit). A cell scraper was 
used to help lyse the cell monolayers. The lysate was col-
lected in a 1.5 ml tube, vortexed for 1 minute, flash frozen in 
liquid nitrogen, and stored at −80 °C before RNA isolation 
according to the manufacturer’s protocol. Subsequently, RNA 
was reverse transcribed using Superscript-III (Invitrogen) 
reverse transcriptase. Reverse transcription was followed by 
PCR analysis of exon 105 of the COL7A1 gene using primary 
(forward 5’-TCAGCTGTGATCCTGGGGCCT-3’; reverse 
5’-AGGGCAGCAAGGGAGAGCCT-3’) and nested (forward 
5’-AGGGCAGCAAGGGAGAGCCT-3’; reverse 5’-TTTGT-
GTCCTGCCAGCCCGG-3’) primers.
For the analysis of type VII collagen expression, cells were 
grown on glass coverslips (Menzel-Gläser, Braunschweig, 
Germany) in 12-well plates. The culture medium was removed 
from the wells 72 hours after transfection and the cells were 
washed followed by fixation using an ice-cold 1:1 methanol-
acetone solution followed by air-drying and storage in -20°C. 
IF staining was used to visualize type VII collagen. The cells 
were stained using LH7.2 (gift prof. dr. I.M. Leigh) primary 
and goat anti mouse Alexa488 labeled secondary antibody 
as described.16 Twenty microliters of cell lysates were sepa-
rated using sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis and electroblotted onto 0.45 µm nitrocellulose 
membranes (Millipore, Amsterdam, the Netherlands). Mem-
branes were blocked with blocking buffer (50 mmol/l Tris-HCl 
pH 7.4, 150 mmol/l NaCl, 0.05% Tween-20 with 5% non-fat 
milk). Blots were stained using the rabbit anti collagen VII anti-
bodies LH7.2 in blocking buffer overnight at 4 °C. Horseradish 
peroxidase-conjugated goat anti-rabbit antibody was added 
for 1 hour. Enhanced chemiluminescence prime reagent (GE 
Healthcare, Chicago, IL) was used to develop blots and pic-
tures were captured using a Fusion SL system (Peqlab, Darm-
stadt, Germany). For dot blot analysis, 200 µl of conditioned 
medium were immobilized on a 0.45 µm nitrocellulose mem-
brane using a Bio-Dot microfiltration apparatus (Bio-Rad, Her-
cules, CA). The membranes were blocked with 5% (w/v) skim 
milk powder (Applichem, Darmstadt, Germany) in Tris-buff-
ered saline with 0.1% (v/v) Tween-20 (Sigma-Aldrich, Saint 
Louis, Missouri, USA) for 30 minutes at RT, and incubated 
with the polyclonal LH7.2 antibody dissolved in blocking buffer 
for 30 minutes at RT. After washing three times for 5 minutes 
with Tris-buffered saline, the membranes were incubated with 
horseradish peroxidase-conjugated secondary antibody for 30 
minutes at RT. Blots were developed as for Western blots and 
data were recorded with the Fusion software.
Generation of human skin grafts. For the generation of skin 
grafts, a mouse model was used as described.21 Briefly, pri-
mary cultured fibroblasts and keratinocytes were used to 
reconstitute human skin on the back of Atymic nude mice 
(Charles River strain 490). For the validation of the mouse 
model, four mice were grafted using healthy control cells. 
After validation, six mice were grafted with RDEB patient cells. 
After implantation of the silicone grafting chamber, a mixture 
of 6 × 106 fibroblasts and 6 × 106 keratinocytes was seeded in 
the grafting chamber in a total volume of 400 µl in 1% low 
calcium BCS (HyClone) Dulbecco’s Modified Eagle’s Medium 
(DMEM) (Gibco). Prior to use, the BCS was chelexed using 
Chelex-100 (Bio-Rad) resin to remove calcium ions. Eight 
days after implantation, the silicone grafting chamber was 
removed and the wound was left to heal forming a scab in the 
process. Around 10 days postremoval of the grafting chamber, 
the scab fell off and the treatment phase was initiated.
Treatment of the patient mice. Once the scabs fell off, the treat-
ment was started. The treatment scheme was composed of 
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five daily injections of 50 mg/kg of each AON in a 0.15M NaCl 
solution for 8 weeks. The subcutaneous injections were given 
in the trunk of the mice around 7 cm distal to the graft. Four 
mice with patient grafts were treated with the mixture of AON1 
and AON2 solution, and two mice with patient grafts and two 
mice with control grafts were injected with saline solutions as 
negative controls.
In vivo RNA and protein analysis. One day after the last injec-
tion of 8 weeks of treatment, the mice were sacrificed and the 
skin grafts were harvested. The entire full skin thickness grafts 
were removed from the back of the mice and flash frozen 
using liquid nitrogen and stored at −80 °C for further analysis. 
For the analysis of exon skipping at the RNA level, a cryosec-
tion of 50 µm was cut on a Leica CM3050S cryostat and RNA 
was isolated, reverse transcribed, and PCR was performed 
as described above. For the analysis of human type VII colla-
gen expression, 4 µm cryosections were stained using Zenon 
(Thermo Fisher Scientific, Life Technologies) labeled LH7.2 
monoclonal mouse-anti-human antibody. Cell nuclei were 
stained using Hoechst. Sections were analyzed using a Leica 
DMRA fluorescence microscope. Calbiochem polyclonal rab-
bit-anti-human antibodies were used for indiscriminative type 
VII collagen staining. Silenus monoclonal PHM12 mouse- 
anti-human was used for type IV collagen staining.
Supplementary material
Figure S1. Clinical pictures of RDEB patient with stop muta-
tion in exon 105.
Figure S2. Validation of the skin-humanized mouse model.
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